Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results. (4th October 2019)

• Record Type: Journal Article
• Authors: MacInnis, Robert J; Liao, Yuyan; Knight, Julia A; Milne, Roger L; Whittemore, Alice S; Chung, Wendy K; Leoce, Nicole; Buchsbaum, Richard; Zeinomar, Nur; Dite, Gillian S; Southey, Melissa C; Goldgar, David; Giles, Graham G; McLachlan, Sue-Anne; Weideman, Prue C; Nesci, Stephanie; Friedlander, Michael L; Glendon, Gord; Andrulis, Irene L; John, Esther M; Daly, Mary B; Buys, Saundra S; Phillips, Kelly Anne; Hopper, John L; Terry, Mary Beth
• Is Part Of: Journal of the National Cancer Institute. Volume 112:Number 4(2020)
• Page Start: 418
• Page End: 422
• Publication Date: 2019-10-04
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; 616.994
• DOI: 10.1093/jnci/djz194
• Languages: English
• ISSNs: 0027-8874

Abstract

Abstract: The performance of breast cancer risk models for women with a family history but negative BRCA1 and/or BRCA2 mutation test results is uncertain. We calculated the cumulative 10-year invasive breast cancer risk at cohort entry for 14 657 unaffected women (96.1% had an affected relative) not known to carry BRCA1 or BRCA2 mutations at baseline using three pedigree-based models (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, BRCAPRO, and International Breast Cancer Intervention Study). During follow-up, 482 women were diagnosed with invasive breast cancer. Mutation testing was conducted independent of incident cancers. All models underpredicted risk by 26.3%–56.7% for women who tested negative but whose relatives had not been tested (n = 1363; 63 breast cancers). Although replication studies with larger sample sizes are needed, until these models are recalibrated for women who test negative and have no relatives tested, caution should be used when considering changing the breast cancer risk management intensity of such women based on risk estimates from these models.